Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting
02 Novembro 2023 - 11:00AM
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage
biopharmaceutical company focused on developing medicines to target
hypertension, chronic kidney disease (CKD) and other diseases
driven by abnormally elevated aldosterone, today presented a new
post-hoc analysis from the Target-HTN Phase 2 trial of
lorundrostat, a highly selective aldosterone synthase inhibitor, in
individuals with uncontrolled hypertension (uHTN) and resistant
hypertension (rHTN). The data were presented during the
Late-Breaking Posters session at the American Society of Nephrology
(ASN) Kidney Week 2023, which is being held in Philadelphia from
November 2–5.
In this new analysis, investigators identified a population of
responders to lorundrostat who experienced a median reduction in
systolic blood pressure (BP) of 32 millimeters of mercury (mmHg).
The enhanced response was proportional to the elevation in body
mass index (BMI) and may indicate an obesity-related,
aldosterone-dependent hypertensive endotype.
“We were able to show in this post-hoc analysis additional
evidence corroborating the association between BMI and blood
pressure reduction with lorundrostat. Individuals trying to manage
obesity and hypertension in tandem are at an increased risk for
poor outcomes, and a treatment that can provide an enhanced
response to this population holds great promise,” stated David
Rodman, M.D., Chief Medical Officer for Mineralys. “We continue to
believe that we’re entering a precision-medicine era when it comes
to hypertension treatments – an era in which physicians can
identify and confidently prescribe an anti-hypertensive treatment
for each patient according to their underlying biological factors,
such as obese individuals with aldosterone-dependent
hypertension.”
Consistent with the pre-specified categorical analysis from
Target-HTN that demonstrated an enhanced treatment response in
individuals with an elevated BMI, a post-hoc linear regression
analysis demonstrated a statistically significant association
between BMI and reduction in systolic BP in subjects with a BMI
ranging from 22.5 to 40kg/m2. The modeled reduction in observed
systolic BP was approximately 12mmHg at a BMI of 30kg/m2, and
19mmHg at a BMI of 40kg/m2. The distribution of responses was
substantially left-skewed, with the upper quartile of subjects
having a median reduction in systolic BP of approximately
32mmHg.
The Target-HTN trial demonstrated that treatment with
lorundrostat at doses of 50mg and 100mg once daily (QD) led to a
statistically and clinically significant reduction of systolic BP
in uncontrolled hypertensive individuals on at least two background
antihypertensive medications. Full results from the trial were
published in the Journal of the American Medical Association (JAMA)
and simultaneously presented during a late-breaking science session
at the 2023 American Heart Association (AHA) Hypertension
Scientific Sessions in September.
Target-HTN trial results support the transition to late-stage
development of lorundrostat as a treatment for uncontrolled and
resistant hypertension. The Company’s ongoing pivotal development
program for lorundrostat to treat uHTN and rHTN is currently
enrolling subjects in the Advance-HTN trial, and the Phase 3
Launch-HTN trial is expected to be initiated before the end of the
year.
The late-breaking poster at ASN Kidney Week 2023, titled,
“Identification of a Hypertensive Endotype with a Median Treatment
Effect of -32 mmHg in Response to the Novel Aldosterone Synthase
Inhibitor Lorundrostat,” can be accessed on the publications page
of the Mineralys corporate website.
About Target-HTNThe Target-HTN (NCT05001945)
Phase 2 proof-of-concept trial was a randomized, double-blind,
placebo-controlled, dose-ranging, multicenter trial conducted in
the U.S. The trial was designed to evaluate the safety, efficacy,
tolerability and dose response of orally administered lorundrostat
on BP for the treatment of uncontrolled and resistant hypertension
when used as add-on therapy to stable background treatment of two
or more antihypertensive agents in 200 male and female subjects 18
years of age or older. Five active doses of lorundrostat (12.5mg
QD, 50mg QD, 100mg QD, 12.5mg twice daily (BID), and 25mg BID) were
compared to placebo in hypertensive subjects. Adverse events
observed were a modest increase in serum potassium, decrease in
estimated glomerular filtration rate, urinary tract infection and
hypertension with one serious adverse event possibly related to
study drug being hyponatremia.
About HypertensionHaving sustained, elevated
blood pressure (or hypertension) increases the risk of heart
disease, heart attack and stroke, which are leading causes of death
in the U.S. In 2020, more than 670,000 deaths in the U.S. included
hypertension as a primary or contributing cause. Hypertension and
related health issues resulted in an average annual economic burden
of about $130 billion each year in the U.S., averaged over 12 years
from 2003 to 2014.
Less than 50 percent of hypertension patients achieve their
blood pressure goal with currently available medications.
Abnormally elevated aldosterone levels are a key factor in driving
hypertension in approximately 25 percent of all hypertensive
patients.
About LorundrostatLorundrostat is a
proprietary, orally administered, highly selective aldosterone
synthase inhibitor being developed for the treatment of
uncontrolled hypertension and CKD. Lorundrostat was designed to
reduce aldosterone levels by inhibiting CYP11B2, the enzyme
responsible for its production. Lorundrostat has 374-fold
selectivity for aldosterone-synthase inhibition versus
cortisol-synthase inhibition in vitro, an observed half-life of
10-12 hours and demonstrated approximately a 70% reduction in
plasma aldosterone concentration in hypertensive subjects.
About Mineralys TherapeuticsMineralys
Therapeutics is a clinical-stage biopharmaceutical company focused
on developing medicines to target hypertension, CKD and other
diseases driven by abnormally elevated aldosterone. Its initial
product candidate, lorundrostat, is a proprietary, orally
administered, highly selective aldosterone synthase inhibitor that
Mineralys Therapeutics is developing for cardiorenal conditions
affected by abnormally elevated aldosterone, including hypertension
and CKD. Mineralys is based in Radnor, Pennsylvania, and was
founded by Catalys Pacific. For more information, please visit
https://mineralystx.com. Follow Mineralys on LinkedIn and
Twitter.
Forward-Looking StatementsMineralys
Therapeutics cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. The forward-looking statements are
based on our current beliefs and expectations and include, but are
not limited to, statements regarding: the potential therapeutic
benefits of lorundrostat; the Company’s expectation that
aldosterone synthase inhibitors with an SGLT2 inhibitor may provide
additive clinical benefits to patients; the Company’s expectation
that the Advance-HTN and the planned Phase 3 clinical trial of
lorundrostat may serve as pivotal trials in any submission of a new
drug application (NDA) to the United States Food and Drug
Administration (FDA); the Company’s ability to evaluate
lorundrostat as a potential treatment for CKD or uncontrolled
hypertension; the planned future clinical development of
lorundrostat and the timing thereof; and the expected timing of
commencement and enrollment of patients in clinical trials and
topline results from clinical trials. Actual results may differ
from those set forth in this press release due to the risks and
uncertainties inherent in our business, including, without
limitation: our future performance is dependent entirely on the
success of lorundrostat; potential delays in the commencement,
enrollment and completion of clinical trials and nonclinical
studies; later developments with the FDA may be inconsistent with
the feedback from the completed end of Phase 2 meeting, including
whether the proposed pivotal program will support registration of
lorundrostat which is a review issue with the FDA upon submission
of an NDA; our dependence on third parties in connection with
manufacturing, research and clinical and nonclinical testing;
unexpected adverse side effects or inadequate efficacy of
lorundrostat that may limit its development, regulatory approval
and/or commercialization; unfavorable results from clinical trials
and nonclinical studies; results of prior clinical trials and
studies of lorundrostat are not necessarily predictive of future
results; our ability to maintain undisrupted business operations
due to any pandemic or future public health concerns; regulatory
developments in the United States and foreign countries; our
reliance on our exclusive license with Mitsubishi Tanabe Pharma to
provide us with intellectual property rights to develop and
commercialize lorundrostat; and other risks described in our
filings with the Securities and Exchange Commission (SEC),
including under the heading “Risk Factors” in our annual report on
Form 10-K, and any subsequent filings with the SEC. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and we
undertake no obligation to update such statements to reflect events
that occur or circumstances that exist after the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement, which is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995.
Contact:Investor
Relationsinvestorrelations@mineralystx.com
Media RelationsTom WeibleElixir
Health Public RelationsPhone: (1) 515-707-9678Email:
tweible@elixirhealthpr.com
Mineralys Therapeutics (NASDAQ:MLYS)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Mineralys Therapeutics (NASDAQ:MLYS)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024